Skip to main content
Molecular & Cellular Proteomics

Main menu

  • Home
  • Articles
    • Current Issue
    • Papers in Press
    • Reviews and Minireviews
    • Special Issues
    • Editorials
    • Archive
    • Letters to the Editor (eLetters)
  • Info for
    • Authors
      • Editorial Policies
      • How to Submit
      • Manuscript Contents & Organization
      • Data Reporting Requirements
      • Publication Charges
    • Reviewers
    • Librarians
    • Advertisers
    • Subscribers
  • Guidelines
    • Proteomic Identification
      • Checklist (PDF)
      • Instructions for Annotated Spectra
      • Tutorial (PDF)
    • Clinical Proteomics
      • Checklist (PDF)
    • Glycomic Identification
      • Checklist (PDF)
    • Targeted Proteomics
      • Checklist (PDF)
    • Data-Independent Acquisition
      • Checklist (PDF)
    • Frequently Asked Questions
  • About
    • Mission Statement and Scope
    • Editorial Policies
    • Editorial Board
    • MCP Lectureships
    • Permissions and Licensing
    • Partners
    • Alerts
    • Contact Us

Submit

  • Submit
  • Publications
    • ASBMB
    • Molecular & Cellular Proteomics
    • Journal of Biological Chemistry
    • Journal of Lipid Research

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
  • Publications
    • ASBMB
    • Molecular & Cellular Proteomics
    • Journal of Biological Chemistry
    • Journal of Lipid Research
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Molecular & Cellular Proteomics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Papers in Press
    • Reviews and Minireviews
    • Special Issues
    • Editorials
    • Archive
    • Letters to the Editor (eLetters)
  • Info for
    • Authors
      • Editorial Policies
      • How to Submit
      • Manuscript Contents & Organization
      • Data Reporting Requirements
      • Publication Charges
    • Reviewers
    • Librarians
    • Advertisers
    • Subscribers
  • Guidelines
    • Proteomic Identification
      • Checklist (PDF)
      • Instructions for Annotated Spectra
      • Tutorial (PDF)
    • Clinical Proteomics
      • Checklist (PDF)
    • Glycomic Identification
      • Checklist (PDF)
    • Targeted Proteomics
      • Checklist (PDF)
    • Data-Independent Acquisition
      • Checklist (PDF)
    • Frequently Asked Questions
  • About
    • Mission Statement and Scope
    • Editorial Policies
    • Editorial Board
    • MCP Lectureships
    • Permissions and Licensing
    • Partners
    • Alerts
    • Contact Us
  • Submit
Review

Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides

Arie Admon, Eilon Barnea and Tamar Ziv
Molecular & Cellular Proteomics June 1, 2003, First published on June 23, 2003, 2 (6) 388-398; https://doi.org/10.1074/mcp.R300004-MCP200
Arie Admon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eilon Barnea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamar Ziv
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The major histocompatibility complex (MHC) peptide repertoire of cancer cells serves both as a source for new tumor antigens for development of cancer immunotherapy and as a rich information resource about the protein content of the cancer cells (their proteome). Thousands of different MHC peptides are normally displayed by each cell, where most of them are derived from different proteins and thus represent most of the cellular proteome. However, in contrast to standard proteomics, which surveys the cellular protein contents, analyses of the MHC peptide repertoire correspond more to the rapidly degrading proteins in the cells (i.e. the transient proteome). MHC peptides can be efficiently purified by affinity chromatography from membranal MHC molecules, or preferably following transfection of vectors for expression of recombinant soluble MHC molecules. The purified peptides are resolved and analyzed by capillary high-pressure liquid chromatography-electrospray ionization-tandem mass spectrometry, and the data are deciphered with new software tools enabling the creation of large databanks of MHC peptides displayed by different cell types and by different MHC haplotypes. These lists of identified MHC peptides can now be used for searching new tumor antigens, and for identification of proteins whose rapid degradation is significant to cancer progression and metastasis. These lists can also be used for identification of new proteins of yet unknown function that are not detected by standard proteomics approaches. This review focuses on the presentation, identification and analysis of MHC peptides significant for cancer immunotherapy. It is also concerned with the aspects of human proteomics observed through large-scale analyses of MHC peptides.

Footnotes

  • Published, MCP Papers in Press, June 23, 2003, DOI 10.1074/mcp.R300004-MCP200

  • ↵1 The abbreviations used are: MHC, major histocompatibility complex; sMHC, soluble major histocompatibility complex; HLA, human leukocytes antigen; TCR, T cell receptor; TSA, tumor-specific antigens; TAA, tumor-associated antigens; SEREX, serological identification of antigens by recombinant expression cloning; ER, endoplasmic reticulum; LC, liquid chromatography; MS, mass spectrometry; MS/MS, tandem mass spectrometry; ORF, open reading frame.

  • ↵2 Beer, I., Barnea, E., Ziv, T., and Admon, A., submitted for publication.

  • ↵* This work was supported by The Greta Koppel Small Cell Lung Cancer Fund and by the Smoler Proteomics Center at the Technion and by the Israel Ministry of Science. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received May 15, 2003.
    • Revision received June 23, 2003.
  • © 2003 The American Society for Biochemistry and Molecular Biology
View Full Text
PreviousNext
Back to top
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Molecular & Cellular Proteomics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides
(Your Name) has sent you a message from Molecular & Cellular Proteomics
(Your Name) thought you would like to see the Molecular & Cellular Proteomics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides
Arie Admon, Eilon Barnea, Tamar Ziv
Molecular & Cellular Proteomics June 1, 2003, First published on June 23, 2003, 2 (6) 388-398; DOI: 10.1074/mcp.R300004-MCP200

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Request Permissions

Share
Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides
Arie Admon, Eilon Barnea, Tamar Ziv
Molecular & Cellular Proteomics June 1, 2003, First published on June 23, 2003, 2 (6) 388-398; DOI: 10.1074/mcp.R300004-MCP200
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

In this issue

Molecular & Cellular Proteomics: 2 (6)
Molecular & Cellular Proteomics
Vol. 2, Issue 6
1 Jun 2003
  • Table of Contents
  • About the Cover
  • Index by author

View this article with LENS

Jump to section

  • Article
    • Abstract
    • LOOKING AT THE PROTEOME FROM THE POINT OF VIEW OF THE IMMUNE SYSTEM
    • TUMOR IMMUNOLOGY
    • SEARCHING FOR TAAS BY PROTEOMICS
    • MHC PEPTIDES AS TAAS
    • IDENTIFICATION OF HLA PEPTIDES AS CANCER VACCINE CANDIDATES
    • BIOASSAYS: TESTING THE IMMUNOGENICITY OF MHC PEPTIDES
    • LOOKING AT THE CELLULAR PROTEOME FROM THE POINT OF VIEW OF THE MHC PEPTIDES
    • FUTURE DIRECTIONS
    • CONCLUSIONS
    • Footnotes
    • REFERENCES
  • eLetters
  • Info & Metrics
  • PDF

  • Follow MCP on Twitter
  • RSS feeds
  • Email

Articles

  • Current Issue
  • Papers in Press
  • Archive

For Authors

  • Submit a Manuscript
  • Info for Authors

Guidelines

  • Proteomic Identification
  • Clinical Proteomics
  • Glycomic Identification
  • Targeted Proteomics
  • Frequently Asked Questions

About MCP

  • About the Journal
  • Permissions and Licensing
  • Advertisers
  • Subscribers

ASBMB Publications

  • Molecular & Cellular Proteomics
  • Journal of Biological Chemistry
  • Journal of Lipid Research
  • ASBMB Today

© 2019 American Society for Biochemistry and Molecular Biology | Privacy Policy

MCP Print ISSN 1535-9476 Online ISSN 1535-9484

Powered by HighWire